Detalhe da pesquisa
1.
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer.
Cell
; 184(25): 6119-6137.e26, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34890551
2.
Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer.
Nature
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588697
3.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature
; 603(7903): 942-948, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35322232
4.
Biomarker-Guided Development of DNA Repair Inhibitors.
Mol Cell
; 78(6): 1070-1085, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32459988
5.
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Br J Cancer
; 130(3): 476-482, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135713
6.
FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
J Hepatol
; 2024 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38508240
7.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
N Engl J Med
; 384(13): 1191-1203, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789008
8.
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Future Oncol
; 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38348690
9.
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
Cancer
; 129(12): 1904-1918, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042037
10.
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.
Oncologist
; 28(5): 425-432, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807743
11.
SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach.
Mod Pathol
; 36(6): 100183, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37054973
12.
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
Future Oncol
; 19(11): 739-752, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36919706
13.
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.
Nature
; 547(7664): 453-457, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28678785
14.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet
; 398(10294): 27-40, 2021 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34102137
15.
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Oncologist
; 26(7): 610-618, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33604969
16.
Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.
Pancreatology
; 2021 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34023183
17.
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(6): 796-807, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32416072
18.
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Invest New Drugs
; 38(2): 419-432, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31020608
19.
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Invest New Drugs
; 38(5): 1483-1494, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32189093
20.
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Lancet Oncol
; 20(8): 1070-1082, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31262657